You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
52 Week High
52 Week Low
Simply Wall StMar 21
Have Insiders Been Buying Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), you may well want to know whether insiders have been buying or selling. Do Insider Transactions Matter? Most investors know that it is quite permissible for company leaders, such as directors of the ...
Yahoo FinanceMar 20
These Four Marijuana Stocks Are Bringing The Heat On Wednesday
CORAL GABLES, FL / ACCESSWIRE / March 20, 2019 / The marijuana stock market has exhibited great promise in the month of March, resulting in the excitement surrounding the cannabis industry.
-$0.65 per share
-$0.44 per share